AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17035947
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (a single dose of 18.4 Gy)
Trial: 12964797
Drug: ACE Surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE Surgical resorbable blast media (RBM) dental implant
Trial: 10846695
Drug: 6 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Trial: 10846695
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Trial: 9356566
Drug: Panic Disorder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panic Disorder Severity Scale (after short-term treatment)
Trial: 3769163
Drug: Amiodarone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone plus type IA agent (group 2, 17 patients)
Trial: 3769163
Drug: Procainamide (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (administered during amiodarone therapy)
Trial: 30589027
Drug: Hypofractionated SIB-IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated SIB-IMRT at 3.6 Gy/f (total of 72 Gy/20 fractions) combined with temozolomide (TMZ) at 75 mg/m2/day during radiotherapy and 150-200 mg/m2/day for 5 days every 28 days.
Trial: 30589027
Drug: Hypofractionated SIB-IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated SIB-IMRT at 4 Gy/f (considered dose-limiting toxicity)
Trial: 26439785
Drug: CRE (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRE (5 g of CRE monohydrate, 4 times per day; n = 14)
Trial: 26439785
Drug: CRE +
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRE + CAF (CRE + 300 mg·d of CAF; n = 13)
Trial: 26439785
Drug: CRE +
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRE + COF (CRE + 8.9 g of COF, yielding 303 mg of CAF; n = 13)
Trial: 23229691
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intravitreal triamcinolone acetonide
Trial: 23229691
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and triamcinolone treatments
Trial: 15602501
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral D‐amphetamine
Trial: 15602501
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral D‐amphetamine
Trial: 23318559
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (twice normal dietary levels)
Trial: 18681892
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple eradication therapy + Saccharomyces boulardii (250 mg b.i.d. for 4 weeks)
Trial: 18681892
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple eradication therapy (omeprazole/esomeprazole, amoxicillin and clarithromycin)
Trial: 18681892
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple eradication therapy + Saccharomyces boulardii
Trial: 18681892
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple eradication therapy
Trial: 16626572
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug therapy and percutaneous coronary intervention (PCI)
Trial: 9477031
Drug: Cognitive approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive approach treatment (n = 9)
Trial: 9477031
Drug: Relaxation component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation component treatment (n = 12)
Trial: 3299568
Drug: Ambroxol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (10 mg/kg, i.v. twice daily for 7 days)
Trial: 23291937
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored educational web pages addressing specific vaccine concerns
Trial: 14557454
Drug: GHRH antagonist
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH antagonist infusion
Trial: 10805184
Drug: albendazole therapy
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: albendazole therapy
Trial: 8927671
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg fluoxetine weekly
Trial: 7104182
Drug: Indomethacin retard
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin retard 75 mg twice daily
Trial: 7104182
Drug: Indomethacin capsules
RxNorm normalized name: Indomethacin Capsules
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin capsules 50 mg three times daily
Trial: 7104182
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg suppository at night with 50 mg by mouth each morning
Trial: 7104182
Drug: Indomethacin retard
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin retard therapy
Trial: 27180314
Drug: Ibogaine 20
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibogaine 20 mg
Trial: 22429766
Drug: Recent regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent regular aspirin use
Trial: 22429766
Drug: Recent regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent regular ibuprofen use
Trial: 9076841
Drug: Policosanol 10
RxNorm normalized name: policosanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 10 mg day-1
Trial: 9076841
Drug: Policosanol 20
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 20 mg day-1
Trial: 9076841
Drug: Policosanol 40
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 40 mg day-1
Trial: 1859490
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 7.5 mg weekly, increased based on clinical improvement
Trial: 1859490
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 100 mg daily, increased based on clinical improvement
Trial: 31705307
Drug: artificial saliva
RxNorm normalized name: ARTIFICIAL SALIVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artificial saliva solution (negative control)
Trial: 29352829
Drug: Multiple-micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-micronutrient powder (daily dose for 3 months)
Trial: 24673045
Drug: Far-infrared therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far-infrared therapy
Trial: 12161488
Drug: One etonogestrel
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One etonogestrel implant
Trial: 12161488
Drug: Two etonogestrel
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two etonogestrel implants
Trial: 12161488
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline testosterone treatment)
Trial: 10198397
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF, 300 microgram sc)
Trial: 7762524
Drug: Rectal acetate
RxNorm normalized name: Rectal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetate (12.5 mmol [1,2‐13C]sodium acetate)
Trial: 7762524
Drug: Intravenous acetate
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetate (12.5 mmol [1,2‐13C]sodium acetate)
Trial: 7762524
Drug: Rectal acetate
RxNorm normalized name: Rectal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetate with propionate (6 mmol sodium propionate)
Trial: 24846822
Drug: Hydromorphone ER
RxNorm normalized name: hydromorphone Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone ER (8-32 mg)
Trial: 24846822
Drug: Oxycodone CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone CR (10-40 mg)
Trial: 18931525
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) treatment for 10 days
Trial: 18931525
Drug: Meta-analysis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-analysis of hydrocortisone treatment
Trial: 16134519
Drug: Transamin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transamin 1.0 g i.v.
Trial: 16134519
Drug: Transamin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transamin 0.5 g i.v.
Trial: 16134519
Drug: aminomethylbenzoic acid
RxNorm normalized name: aminomethylbenzoic acid
DrugBank: Aminomethylbenzoic acid (DB13244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminomethylbenzoic acid 0.5 g i.v.
Trial: 8048854
Drug: Histamine blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine blocker treatment for hemorrhagic ulcers
Trial: 3393383
Drug: Piperacillin 600
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin 600 mg/kg/day (P)
Trial: 3393383
Drug: Piperacillin 600
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin 600 mg/kg/day plus tobramycin (PT)
Trial: 23079690
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg delayed-release (DR) weekly (FB)
Trial: 23079690
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg delayed-release (DR) weekly (BB)
Trial: 21570934
Drug: Biological causal
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological causal model
Trial: 21570934
Drug: Combined causal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined causal model (biological and psychological)
Trial: 1321509
Drug: Enoxaparin, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin, 30 mg subcutaneously every 12 h for up to 14 days
Trial: 27509020
Drug: Celgosivir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celgosivir (400 mg loading dose and 200 mg bid over 5 days)
Trial: 20685721
Drug: Conventional transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional transcutaneous electrical nerve stimulation treatment
Trial: 7517256
Drug: Oral gammaglobulin
RxNorm normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gammaglobulin (50 mg/kg daily in four divided doses for 28 days)
Trial: 2560521
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (estrone sulfate) at a dose of 1.25 mg/day for 6 weeks
Trial: 30355445
Drug: LSD (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (100 µg po)
Trial: 26780757
Drug: Bridging with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging with low-molecular-weight heparin during interruption of vitamin K antagonists
Trial: 24118931
Drug: Twice-daily premixed
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily premixed protamine-aspart/aspart insulin (PM-2)
Trial: 24118931
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin glargine plus zero to one prandial insulin glulisine injection (G+1)
Trial: 24118931
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus zero to three prandial injections (G+3)
Trial: 19841158
Drug: Silymarin (140,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140, 280, 560, or 700 mg every 8 hours for 7 days)
Trial: 11061613
Drug: CV6504, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV6504, 100 mg TDS, orally for three months
Trial: 1617044
Drug: Cefprozil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil (500 mg twice daily)
Trial: 1617044
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (500 mg twice daily)
Trial: 1617044
Drug: Amoxicillin/clavulanate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (500 mg/125 mg three times daily)
Trial: 6143188
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (5 exchanges in 10 days, 55 ml plasma/kg body weight/exchange)
Trial: 29290066
Drug: Tanning behaviors
RxNorm normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanning behaviors (indoor tanning, concurrent tanning types)
Trial: 23173253
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of meloxicam
Trial: 7798511
Drug: Bamiphylline (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamiphylline (selective antagonist of A1 adenosine receptors)
Trial: 3674851
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (500 or 250 mg twice daily) for 7 days
Trial: 3674851
Drug: Amoxycillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (250 mg three times daily)
Trial: 29090846
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg plus laser (COMBI)
Trial: 29090846
Drug: Laser monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser monotherapy (LASER)
Trial: 26652026
Drug: MD2011001 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD2011001 cream
Trial: 25109413
Drug: GSK1070806 (0.008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1070806 (0.008 - 10 mg/kg)
Trial: 23543663
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D₃ supplements (Control)
Trial: 19787287
Drug: PCD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCD therapy
Trial: 11561116
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily) in females with primary Raynaud's phenomenon
Trial: 11561116
Drug: Nifedipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (40 mg daily) in females with primary Raynaud's phenomenon
Trial: 9115059
Drug: Lidocaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (10 mg/mL)
Trial: 9115059
Drug: Guanethidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanethidine (2 mg/mL)
Trial: 9115059
Drug: Nicardipine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (0.2 mg/mL)
Trial: 9115059
Drug: Nitroglycerin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.3 mg/mL)
Trial: 9115059
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (1 microgram/mL)
Trial: 24486335
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron 8 mg
Trial: 3034469
Drug: Cilazapril 2.5
RxNorm normalized name: cilazapril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5 mg/day for 15 days
Trial: 31404469
Drug: Osteopathic Manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Manipulative Therapy (OMTh) for 3 months
Trial: 29987329
Drug: CGRP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGRP infusion (1.5 μg/min over 20 minutes)
Trial: 26871700
Drug: Triamcinolone (TA)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone (TA) 4 mg
Trial: 23006898
Drug: Hydrocortisone (stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (stress doses)
Trial: 17266687
Drug: Octreotide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.3 mg) administered via continuous intravenous infusion for 6 hours, starting 1 hour before ERCP, with additional subcutaneous injections of 0.1 mg at 6 and 12 hours after infusion stopped.
Trial: 17266687
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously.
Trial: 9469172
Drug: Attention/support control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention/support control treatment
Trial: 8593922
Drug: Des(64,65)-proinsulin (DPRO)
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Des(64,65)-proinsulin (DPRO) at doses of 0.1, 0.15, 0.2 U/kg
Trial: 8593922
Drug: NPH-insulin at
RxNorm normalized name: Neutral Protamine Hagedorn (NPH) insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH-insulin at doses of 0.2, 0.3, 0.4 U/kg
Trial: 1115339
Drug: AH 8165,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH 8165, 1 times 25 mg/kg
Trial: 1115339
Drug: Suxamethonium, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium, 1 mg/kg
Trial: 25497244
Drug: Warfarin (continuing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (continuing on VKA)
Trial: 25497244
Drug: Warfarin (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (for warfarin-naive patients)
Trial: 23381685
Drug: Transdiagnostic cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic cognitive‐behavioral therapy intervention (up to 18 weeks)
Trial: 19658033
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment received
Trial: 16372352
Drug: Inhaled recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 500 mg
Trial: 16372352
Drug: Inhaled recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 250 mg
Trial: 16372352
Drug: Inhaled recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled recombinant human alpha(1)-antitrypsin (rAAT)
Trial: 14526711
Drug: Acupuncture; details
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture; details on dosage and duration not available.
Trial: 10539706
Drug: Spira Elektro
RxNorm normalized name: Lavandula spica oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spira Elektro 4 jet nebulizer with budesonide (0.5 mg)
Trial: 10539706
Drug: Spira Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spira Ultra ultrasonic nebulizer with budesonide (0.5 mg)
Trial: 10539706
Drug: Spira Elektro
RxNorm normalized name: Lavandula spica oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spira Elektro 4 jet nebulizer with terbutaline (5.0 mg)
Trial: 10539706
Drug: Spira Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spira Ultra ultrasonic nebulizer with terbutaline (5.0 mg)
Trial: 6846920
Drug: Albuterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (100 and 200 micrograms)
Trial: 30255204
Drug: Posterior pillar
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior pillar mucosal suspension technique (Group A)
Trial: 18823336
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glibenclamide and diclofenac
Trial: 17155990
Drug: Neoadjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormone therapy (HT)
Trial: 3137605
Drug: DL-threo-3,4-dihydroxyphenylserine (DOPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-threo-3,4-dihydroxyphenylserine (DOPS) 1 g dose
Trial: 25989386
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment before hemodynamic control
Trial: 25989386
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to medical treatment
Trial: 25989386
Drug: Nonresponders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponders to medical treatment (variceal band ligation)
Trial: 25989386
Drug: TIPS and
RxNorm normalized name: Burt's Bees Tips and Toes Kit Gift Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIPS and medical treatment